These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36032766)

  • 1. Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment.
    Liu Y; Guo Q; Yang H; Zhang XW; Feng N; Wang JK; Liu TT; Zeng KW; Tu PF
    ACS Cent Sci; 2022 Aug; 8(8):1102-1115. PubMed ID: 36032766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Luo F; Lin K
    Exp Cell Res; 2022 Aug; 417(1):113176. PubMed ID: 35489385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma.
    Gutschner T; Hämmerle M; Pazaitis N; Bley N; Fiskin E; Uckelmann H; Heim A; Groβ M; Hofmann N; Geffers R; Skawran B; Longerich T; Breuhahn K; Schirmacher P; Mühleck B; Hüttelmaier S; Diederichs S
    Hepatology; 2014 May; 59(5):1900-11. PubMed ID: 24395596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction.
    Xu Y; Zheng Y; Liu H; Li T
    Int J Oncol; 2017 Sep; 51(3):791-800. PubMed ID: 28677801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression.
    Zhang L; Wan Y; Zhang Z; Jiang Y; Gu Z; Ma X; Nie S; Yang J; Lang J; Cheng W; Zhu L
    Theranostics; 2021; 11(3):1100-1114. PubMed ID: 33391523
    [No Abstract]   [Full Text] [Related]  

  • 6. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-98-5p Inhibits Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma via Targeting IGF2BP1.
    Jiang T; Li M; Li Q; Guo Z; Sun X; Zhang X; Liu Y; Yao W; Xiao P
    Oncol Res; 2017 Aug; 25(7):1117-1127. PubMed ID: 28244848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
    Yan Y; Huang P; Mao K; He C; Xu Q; Zhang M; Liu H; Zhou Z; Zhou Q; Zhou Q; Ou B; Liu Q; Lin J; Chen R; Wang J; Zhang J; Xiao Z
    Oncogene; 2021 Jan; 40(1):28-45. PubMed ID: 33051595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.
    Zhang J; Cheng J; Zeng Z; Wang Y; Li X; Xie Q; Jia J; Yan Y; Guo Z; Gao J; Yao M; Chen X; Lu F
    Oncotarget; 2015 Dec; 6(39):42040-52. PubMed ID: 26547929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive role of microRNA-29 in hepatocellular carcinoma via targeting IGF2BP1.
    Yang J; Gong X; Yang J; Ouyang L; Xiao R; You X; Ouyang Y
    Int J Clin Exp Pathol; 2018; 11(3):1175-1185. PubMed ID: 31938212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
    Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
    Front Oncol; 2019; 9():883. PubMed ID: 31572677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival.
    Lambrianidou A; Sereti E; Soupsana K; Komini C; Dimas K; Trangas T
    Cell Signal; 2021 Apr; 80():109912. PubMed ID: 33388443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
    Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
    Elife; 2021 Nov; 10():. PubMed ID: 34779401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma.
    Zhou X; Zhang CZ; Lu SX; Chen GG; Li LZ; Liu LL; Yi C; Fu J; Hu W; Wen JM; Yun JP
    Oncogene; 2015 Feb; 34(8):965-77. PubMed ID: 24632613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression.
    Wei L; Ling M; Yang S; Xie Y; Liu C; Yi W
    Hum Cell; 2021 Mar; 34(2):539-549. PubMed ID: 33387362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner.
    Cai X; Chen Y; Man D; Yang B; Feng X; Zhang D; Chen J; Wu J
    Cell Death Discov; 2021 Oct; 7(1):315. PubMed ID: 34707107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.